{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-381098","form_type":"8-K","ticker":"APVO","cik":"0001671584","company_name":"Aptevo Therapeutics Inc.","filed_at":"2026-09-03T12:15:14+00:00","discovered_at":"2026-09-03T12:20:01.416886+00:00","generated_at":"2026-09-03T12:20:09.146086+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Aptevo reports 93% clinical benefit rate with mipletamig triplet in TP53-mutated AML","bullets":["Of 14 evaluable TP53-mutated frontline AML patients, 13 (93%) achieved clinical benefit; 11 (79%) achieved CR/CRi, including 9 CRs.","79% CR/CRi compares favorably to published 41% composite remission rate for venetoclax plus azacitidine in this population.","RAINIER dose optimization trial expected to complete by year-end 2026; regulatory interaction planned for 1H27.","Data include two patients from previously completed dose expansion trial; mipletamig combined with venetoclax and azacitidine."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-381098","json":"https://secwatch.observer/filing/0001193125-26-381098.json","markdown":"https://secwatch.observer/filing/0001193125-26-381098.md","text":"https://secwatch.observer/filing/0001193125-26-381098.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671584/000119312526381098/0001193125-26-381098-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671584/000119312526381098/apvo-20260903.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-03T12:20:09.146086+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}